pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER
Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
S005201-175
Phase 3 · small molecule · Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin
S005201-175 for Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin is a Phase 3 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Internal code S005201-175
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- The George Institute
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin
- Status
- active
- Trials
- 1